奥沙利铂在胃癌耐药性中的研究进展

Research Progress of Oxaliplatin in Drug Resistance of Gastric Cancer

胃癌是全世界最常见的癌症死亡原因之一,由于东西方国家的肿瘤生物学差异,确定统一的治疗标准十分困难,目前尚无治疗晚期胃癌的标准方案,全身化疗、放疗、手术、免疫治疗、靶向治疗等均已证实对胃癌有效。早期胃癌的主要治疗方法是内镜下切除,晚期胃癌采用联合化疗方案治疗。随着细胞毒性药物和分子靶向药物的快速发展,晚期胃癌姑息性化疗取得了一定进展,晚期胃癌患者的中位生存期延长至一年左右。奥沙利铂与其他药联合被认定是晚期胃癌一线化疗的新选择,由于不确定的疗效、安全性问题及肿瘤耐药现象的出现,分子靶向药物在晚期胃癌治疗中的作用有待进一步研究。因此,本文就胃癌治疗过程中奥沙利铂耐药的研究进展进行综述。

Gastric cancer is one of the most common causes of cancer death in the world.Due to the biological differences between eastern and western countries,it is very difficult to determine a unified treatment standard.At present,there is no standard scheme for the treatment of advanced gastric cancer.Systemic chemotherapy,radiotherapy,surgery,immunotherapy and targeted therapy have been proved to be effective for gastric cancer.The main treatment of early gastric cancer is endoscopic resection,and late gastric cancer is treated with combined chemotherapy.With the rapid development of cytotoxic drugs and molecular targeted drugs,palliative chemotherapy for advanced gastric cancer has made some progress,and the median survival time of patients with advanced gastric cancer has been extended to about one year.Oxaliplatin combined with other drugs is recognized as a new choice for first-line chemotherapy of advanced gastric cancer.Due to the uncertain curative effect,safety problems and the emergence of tumor drug resistance,the role of molecular targeted drugs in the treatment of advanced gastric cancer needs further study.Therefore,this article reviews the research progress of oxaliplatin resistance in the treatment of gastric cancer.